Skeletal muscle relaxation in general anaesthesia

Active Ingredient: Vecuronium

Indication for Vecuronium

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Vecuronium is indicated as an adjunct to general anaesthesia to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery in adults, neonates, infants, children and adolescents.

For this indication, competent medicine agencies globally authorize below treatments:

0.03-0.10 mg/kg

Route of admnistration


Defined daily dose

0.03 - 0.1 mg per kg of body weight

Dosage regimen

From 0.03 To 0.1 mg per kg of body weight once every day

Detailed description

As with other neuromuscular blocking agents, vecuronium should only be administered by, or under supervision of, experienced clinicians who are familiar with the action and use of these drugs.

As with all other neuromuscular blocking agents, the dosage of vecuronium should be individualised in each patient. The anaesthetic method used, the expected duration of surgery, the possible interaction with other drugs that are administered before or during anaesthesia and the condition of the patient should be taken into account when determining the dose.

The use of an appropriate neuromuscular monitoring technique is recommended to monitor neuromuscular block and recovery.

Inhalational anaesthetics potentiate the neuromuscular blocking effects of vecuronium. This potentiation however, becomes clinically relevant in the course of anaesthesia, when the volatile agents have reached the tissue concentrations required for this interaction. Consequently, adjustments with vecuronium should be made by administering smaller maintenance doses at less frequent intervals or by using lower infusion rates of vecuronium during long lasting procedures (longer than 1 hour) under inhalational anaesthesia.


In adult patients the following dosage recommendations may serve as a general guideline for tracheal intubation and muscle relaxation for short to long lasting surgical procedures.

Tracheal intubation

The standard intubating dose during routine anaesthesia is 80 to 100 micrograms vecuronium bromide per kg body weight, after which adequate intubation conditions are established within 90 to 120 seconds in nearly all patients.

Dosages of vecuronium for surgical procedures after intubation with suxamethonium

Recommended doses: 30 to 50 micrograms vecuronium bromide per kg body weight.

If suxamethonium is used for intubation, the administration of vecuronium should be delayed until the patient has clinically recovered from the neuromuscular block induced by suxamethonium.

Maintenance dosing

The recommended maintenance dose is 20 to 30 micrograms vecuronium bromide per kg body weight.

These maintenance doses should best be given when twitch height has recovered to 25% of control twitch height.

Dose requirements for administration of vecuronium by continuous infusion

If vecuronium is administered by continuous infusion, it is recommended to give a loading dose first and, when neuromuscular block starts to recover, to start administration of vecuronium by infusion.

The infusion rate should be adjusted to maintain twitch response at 10% of control twitch height or to maintain 1 to 2 responses to train of four stimulation.

In adults, the infusion rate required to maintain neuromuscular block at this level, ranges from 0.8 to 1.4 micrograms vecuronium bromide/kg/min. For neonates and infants see below. Repeat monitoring of neuromuscular block is recommended since infusion rate requirements vary from patient to patient and with the anaesthetic method used.

Elderly patients

The same intubation and maintenance doses as for younger adults (80–100 micrograms/kg and 20-30 micrograms/kg, respectively) can be used. However, the duration of action is prolonged in elderly compared to younger subjects due to changes in pharmacokinetic mechanisms. The onset time in elderly is similar to younger adults.

Overweight and obese patients

When used in overweight or obese patients (defined as patients with a body weight of 30% or more above ideal body weight), doses should be reduced taking into account an ideal body weight.

Higher doses

Should there be reason for selection of larger doses in individual patients, initial doses ranging from 150 micrograms up to 300 micrograms vecuronium bromide per kg body weight have been administered during surgery both under halothane and neurolept anaesthesia without adverse cardiovascular effects being noted as long as ventilation is properly maintained. The use of these high dosages of vecuronium pharmacodynamically decreases the onset time and increases the duration of action.

In caesarean section and neonatal surgery the dose should not exceed 100 micrograms/kg.

Paediatric population

Adolescents (12-17 years)

Although there is very little information on dosage in adolescents, it is advised to use the same dose as in adults, based on the physiological development at this age.

Children (2-11 years)

Dose requirements in children are higher than for adults and neonates. However, the same intubation and maintenance doses as for adults (80–100 micrograms/kg and 20-30 micrograms/kg, respectively) are usually sufficient. Since the duration of action is shorter in children, maintenance doses are required more frequently.

Dosage considerations

Vecuronium is administered intravenously either as a bolus injection or as a continuous infusion.

Active ingredient


Vecuronium is a non-depolarising neuromuscular blocking agent. Vecuronium blocks the transmission process between the motor nerve-ending and striated muscle by binding competitively with acetylcholine to the nicotinic receptors located in the motor end-plate region of striated muscle.

Read more about Vecuronium

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.